ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
X-Chem, a Massachusetts-based firm that provides DNA-encoded libraries (DELs) for drug discovery, has acquired IntelliSyn, a Montreal-based medicinal chemistry services firm, and AviSyn, its US affiliate. X-Chem says its DEL platform allows customers to screen billions of compounds simultaneously against a single biological target. Acquiring IntelliSyn, X-Chem says, will allow it to offer those customers medicinal chemistry, custom synthesis, and process scale-up services.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X